




PHARMACEUTICAL 2022

Hillstream BioPharma Inc.
Rank 414 of 475





RealRate

PHARMACEUTICAL 2022

Hillstream BioPharma Inc.
Rank 414 of 475

The relative strengths and weaknesses of Hillstream BioPharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Hillstream BioPharma Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 359% points. The greatest weakness of Hillstream BioPharma Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 289% points.

The company's Economic Capital Ratio, given in the ranking table, is -476%, being 200% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	622
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,534
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	773
Other Net Income	1,001
Property and Equipment	0
Research and Development	1,843
Revenues	0
Selling, General and Administrative Expense	1,365

Output Variable	Value in 1000 USD
Assets	622
Liabilities	5,307
Expenses	3,208
Stockholders Equity	-4,685
Net Income	-2,207
Comprehensive Net Income	-2,207
Economic Capital Ratio	-476%



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai